– FRANCE, Paris – Lysogene (EPA: LYS), a leading Phase 2/3 biopharmaceutical company specializing in gene therapy technology applied to the central nervous system (CNS), today announced that Dr. Mathieu Simon has been appointed by cooptation to the Board as an independent director.
In addition, Karen Aiach, Founder and Chief Executive Officer of Lysogene, has been appointed Chair of the Board of Directors. Ms. Aiach succeeds Annette Clancy who held the post of Chair since 2015.
“We would like to thank Ms. Clancy for her important contribution as Chair of the Board and look forward to continuing to work with her as a director,” said Karen Aiach.
“At the same time, we are delighted to welcome Dr. Simon to the Board of Directors, during this period of exciting progress in our pipeline including our ongoing international Phase 3 clinical trial at Lysogene. Dr. Simon brings a wealth of experience and strategic vision to the company,” she added.
Ms. Clancy will remain on the Board as an independent Director.
“It has been a pleasure to chair Lysogene over the past 4 years and help guide the company through its public listing on Euronext and very importantly secure an excellent partnership with Sarepta last year. This partnership provides an opportunity for MPS IIIA patients to receive a potential life-altering treatment and sets the Company on a growth trajectory to becoming a leading gene therapy company in Europe,” said Annette Clancy.
Lysogene’s Board of Directors is now composed exclusively of independent directors, with the exception of Karen Aiach.
About Dr. Mathieu Simon
A graduate in internal medicine from the Faculty of Medicine of Paris VII, Dr. Simon is Senior Strategic Advisor at Messier Maris & Associés, an international investment bank. He is also an independent Director of Vaximm AG, LNC SA, member of the Supervisory Board of Affimed and a non-executive member of Idorsia Board of Directors. Moreover, Dr. Simon is an advisor to the European Commission – Research and Innovation. He previously held positions of Executive Vice President, Chief Operating Officer of Cellectis, CEO of Cellectis Therapeutics and CEO of Ectycell; Senior Vice President and Head of Global Pharmaceutical Operations at Pierre Fabre SA, as well as general management and senior corporate roles at Wyeth Pharmaceuticals. He was also Chairman of the Board of Directors of Cellartis AB.
Lysogene is a gene therapy company focused on the treatment of orphan diseases of the central nervous system (CNS). The company has built a unique capability to enable safe and effective delivery of gene therapies to the CNS to treat lysosomal diseases and other genetic disorders of the CNS. A pivotal clinical trial in MPS IIIA in partnership with Sarepta Therapeutics, Inc. is ongoing and a phase 1-2 clinical trial in GM1 Gangliosidosis is in preparation. In accordance with the agreements signed between Lysogene and Sarepta Therapeutics, Inc., Sarepta Therapeutics, Inc. will hold exclusive commercial rights to LYS-SAF302 in the United States and markets outside Europe; and Lysogene will maintain commercial exclusivity of LYS-SAF302 in Europe. Lysogene is also collaborating with an academic partner to define the development strategy for the treatment of Fragile X syndrome, a genetic disease related to autism.
For more, www.lysogene.com.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.